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Introduction
Traditional Chinese medicine (TCM) has more than 2000 years 
of history in the prevention and treatment of diseases in 
China (Li et al., 2008), and it plays an indispensable role in the 
Chinese healthcare system. In TCM, several different herbs are 
mixed into a preparation due to their own properties and to be 
therapeutically effective as a whole. This type of compatible 
application of herbs in TCM exhibits holistic effectiveness by 
exerting activities to multiple target organs (organ systems) 
on the basis of the principles of traditional oriental medicine 
(Ma et al., 2009). The pharmacological effects of TCM do not 
only depend on the special chemical components but also the 
physical states of drugs. In TCM, many medicinal materials 
are orally administered directly after grounding into a powder. 
The powders’ particle size affects their pharmaceutical 
behavior, such as solubility; yield of chemical constituents, 
chemical stability, bioavailability and among others. It was 
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A B S T R A C T
Qili Powder, a preparation from Traditional Chinese Medicine, commonly used to treat in-
juries from falling or stumbling, pain caused by bruising, and traumatic hemorrhage. The 
aim of the present work was to investigate the application of the superfine pulverization on 
Qili Powder properties. The physicochemical and medicinal properties of fine Qili Powder 
with D90 particle size of 164.5 μm, and superfine Qili Powder with D90 particle size of 32.2 
μm were investigated. The results showed that with decreasing particle size, the specif-
ic surface area and pore volume increased, the fluidity decreased, and the percentage of 
moisture absorption and the balanced moisture content decreased. Analysis HPLC, XRD and 
FTIR results indicated that superfine pulverization didn’t influence dracorhodin content, 
nor the molecular structure and crystal form of Qili Powder. The percentage of dissolution 
of dracorhodin was significantly improved after superfine pulverization. Pharmacokinetics 
results confirmed that superfine pulverization increases the absorption rate in rats and 
dracorhodin content of Qili Powder.
© 2014 Sociedade Brasileira de Farmacognosia. Published by Elsevier Editora Ltda. All rights reserved.
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found that the water holding capacity and polysaccharide 
solubility significantly improved with the decrease in size of 
Astragalus membranaceus particles (p < 0.05) (Zhao et al., 2010). 
It was reported that after superfine pulverization, the plant 
cell walls of Bai Zhi are broken into pieces and the extraction 
yield of imperatorin increased by 11.93% compared with the 
normal particles (Yang et al., 2011). Su (Su et al., 2009) studied 
the effect of ultrafine grinding on dissolving-out quantity of 
tanshinone IIA from Radix Salvia miltiorrhiza, and the results 
indicated that the molecular structure of the active ingredients 
did not change, the dissolving-out quantity of tanshinone IIA 
increased greatly from 12.77 μg/g to 54.55 μg/g. It was found that 
ultrafine grinding can obviously increase the absorption rate 
and degree of absorption of Liuwei Dihuang in rats (Ma et al., 
2009). Previous investigations from our group showed that loose 
intercellular junction without rupture of the wall could increase 
the dissolution of hydroxysafflor yellow A in Carthamus tinctorius 
L. powders of different sizes (Liao et al., 2010). 
Qili Powder (Chinese Pharmacopoeia Commission, 2010), is 
a TCM preparation, composed of Sanguis draconis (Daemonorops 
draco (Willd.) Blume, Arecaceae), olibanum (Boswellia carteri 
Birdw., Burseraceae), myrrh (Commiphora myrrha (T. Nees) Engl., 
Burseraceae), Flos Carthami (Carthamus tinctorius L., Asteraceae), 
catechu (Acacia catechu (L. f.) Willd., Fabaceae) Borneolum 
syntheticum, musk (Musk berezovskii Flerov) and cinnabar (Red 
mercuric sulfide). The preparation of Qili Powder consists of 
the pulverization of the eight traditional Chinese medicines 
into a fine powder. Qili Powder is well known for its actions of 
resolve stagnant blood to reduce swelling, as a painkiller and 
coagulant. It is used for the treatment of injuries from falling or 
stumbling, pain caused by bruises, and traumatic hemorrhage 
in China. Chemical analyses show that Qili Powder contains 
various pharmacologically active ingredients. Dracorhodin (1), 
one of the main ingredients of Qili Powder, is used to estimate 
the quality of the preparation. Dracorhodin has properties of 
eliminate blood stasis and to ease pain (Ma et al., 2002; 2005), 
and the plasma concentration of dracorhodin of Qili Powder 
is closely related to the efficacy of Qili Powder. Some methods 
have been used to assess dracorhodin content in plants and 
rat plasma (Sousa et al., 2008; Zhao et al., 2011; Yi et al., 
2012). In this study, a sensitive and simple HPLC and LC-MS 
methods were developed and validated for the determination 
of dracorhodin in a sample solution and in rat plasma after 
oral administration of Qili Powder.
The influence of superfine pulverization on the stability of 
Qili Powder was investigated, and the results showed that at 
high temperatures dracorhodin (1) content in the fine powder 
decreased even though there was no other significant change 
in the superfine powder (Wang et al., 2013; Zhao et al., 2013). 
Few studies have reported any other difference between fine 
powder and superfine powder regarding the physical-chemical 
and medicinal characteristics of Qili Powder. The objective of 
the present work was to investigate the effect of the superfine 
pulverization in Qili Powder. 
A comparative study of physicochemical properties (specific 
surface area, morphology analysis, bulk density, moisture 
absorption) and the medicinal characterization (dracorhodin 
dissolution, pharmacokinetics) of superfine and fine Qili powder 
was performed. Through the study to explore the application of 
superfine pulverization technology in Qili Powder.
Materials and methods
Materials
Sanguis draconis was bought from China National Corp. of 
Traditional and Herbal Medicine (Beijing, China) and was kept 
in a cool dry room. Seven other medicinal materials were 
purchased at a local drugstore (Nanchang, China). All medicinal 
materials were identified by Professor Shouwen Zhang, at 
JiangXi University of Traditional Chinese Medicine, and the 
medicinal materials met all requirements from “identification” 
in 2010 Pharmacopoeia of the People’s Republic of China. 
The voucher specimens of these eight plants of Sanguis 
draconis (Nº 063416), olibanum (Nº 085127), myrrh (Nº 085128), 
Flos Carthami (Nº 105412), catechu (No. 063480), Borneolum 
syntheticum (Nº 074501), musk (Nº 050233), and cinnabar (Nº 
078425) were deposited in the Herbarium of the Department 
of Pharmacognosy, JiangXi University of Traditional Chinese 
Medicine. Reference substance, dracorhodin perchlorate, 
was obtained from the National Institute for the Control of 
Pharmaceuticals and Biological Products (Nanchang, China). 
Male Sprague-Dawley rats were bred at the central animal 
facility of JiangXi University of TCM (Nanchang, China) was used. 
The animals were housed under standard conditions with free 
access to food and water. All the animal studies were done in 
accordance with the approved protocols and guidelines of the 
Institutional Animal Ethical Care Committee (Sharma et al., 2005) 
and were approved by the local ethics committee for animal 
experimentation (No. 49101595-1-10). All efforts were made to 
minimize the number of animals used and their suffering.
Preparation of fine Qili powder (FP) 
Cinnabar was grounded to a very fine powder (part I). Sanguis 
draconis, olibanum, myrrh, Flos Carthami and catechu were 
subjected to coarse grinding using a 6202 type high speed 
disintegrator (Huanya-Tianyuan Machine Technology Co., 
Beijing, China) and screened through a sieve (80 mesh) to 
separate granulates (d < 180 μm) (part II). Musk and Borneolum 
syntheticum were triturated into a fine powder (part III). These 
three parts were sifted and mixed thoroughly. 
Preparation of superfine Qili powder (SP) 
The powders part I, part II and part III were put into the 
close delivery kettle of a SYFM-8 II type vibrating ultrafine 
pulverizer (Powder Technology Engineering Co., Ltd, Jinan, 
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China), and processed. The temperature was kept at below 
5°C to prevent musk and Borneolum syntheticum of Qili Powder 
from volatilizing. 
Determination of powder size
The average particle size of the FP and SP was determined by 
dry laser diffraction. Mastersizer 2000 (Malvern instruments 
Ltd., UK) which equipped with Scirocco dry module was 
applied in the test. The intake air pressure and feed-rate of 
operating parameters of the experiment are 2.5 bars and 55%, 
respectively.
Specific surface area and pore volume
The specific surface area and pore volume of the FP and SP 
were determined by nitrogen gas absorption based on the BET 
method (Sousa et al., 2002) using TriStar3000 surface area and 
pore volume analyzer (Micromeritics Instrument Corp., USA).
Morphology analysis
The morphology of the FP and SP was evaluated using a 
MD50 polarizing microscope (Ming-Mei Technology Co., Ltd, 
Guangzhou, China).
Bulk density and the angle of repose 
The bulk density and angle of repose were determined using 
appropriate methods validated previously, by Taser et al. (2005) 
and  Bai et al. (2006), respectively.
Moisture absorption
According to the guiding principle of moisture absorption 
medicine testing of the Pharmacopoeia of the People’s Republic 
of China (Chinese Pharmacopoeia Commission, 2010) to 
determine the moisture absorption of the FP and SP.
Fourier Transform Infrared Spectroscopy (FTIR) and X-ray 
Diffraction (XRD)
FTIR spectra of the FP and SP from 400 to 4000 cm-1 were 
collected by a Vertex70 FTIR (Bruker spectrometer company, 
Germany). The FP and SP XRD was performed using a D8 
ADVANCE X-ray diffraction (Beuker-axs, Germany), with Cu 
KD radiation, voltage 40 kV, current 40mA and scanning range 
of 2T is 5 -50°.
Content of dracorhodin 
The content of dracorhodin (1) in the FP and SP was determined 
by HPLC analysis (Wang et al., 2013).
Dissolution testing 
The dissolution of the FP and SP was tested using 
Pharmacopoeia of the People’s Republic of China (Chinese 
Pharmacopoeia Commission, 2010) type 2 dissolution testing 
apparatus (paddle method). ZRS-8G Intelligent Dissolution 
Tester (Tianda Tianfa Technology Co., Ltd., China) was used 
in this study. The weights of the FP and SP were accurately 
weighed (about 1 g) and put into the vessels with 250 ml double 
distilled water (n = 6); paddle speed was 100 g and temperature 
was 37 ± 0.5°C. Samples were taken at 5, 10, 15, 30, 45, 60, 90, 
120 min, and replaced with an equal volume of the same fresh 
medium. An aliquot of 1.5 ml was filtered through a 0.22 μm 
filter, and the concentration of dracorhodin was determined 
according to the above-mentioned chromatogram condition.
Pharmacokinetics
LC and MS/MS parameters
The quantitative analysis was performed on a 6410 Triple Quad 
LC-MS/MS coupled with an Agilent 1200 HPLC system (Agilent, 
USA). The chromatography was performed using a Kromasoil 
C18 column (150 × 4.6 mm, 5 μm). The mobile phase consisted 
of acetonitrile and 0.1% formic acid in double distilled water 
(55:45 in volume). The flow rate of the mobile phase was set 
at 0.4 ml/min, the column temperature was 35°C, and the 
injection volume was 20 μl. 
The mass spectrometer was operated at ESI positive ion 
mode and detection was performed in the multiple reaction 
monitoring (MRM) modes. The analytes were first characterized 
by Q1 MS (Q1) scan and enhanced product ion (EPI) scan to 
determine the precursor ions and product ions used in MRM 
mode. The MS/MS transitions were: m/z [M+H]+ 267.2 precursor 
ion to the m/z 252 product ion. The ion spray voltage was set at 
3,500 V; ionization temperature was set at 350°C. 
Oral administration
FP/SP suspension was administered orally at a dose of 12.15 g/kg to 
rats. Blood samples of about 0.5 ml were collected in heparinized 
test tubes via the postorbital venous plexus at 0.08, 0.17, 0.25, 0.50, 
0.75, 1, 1.5, 2, 3 , 4, 6, 8, 12, 24, 36, 48, 72 h after administration. 
Blood was separated by centrifugation at 4000× g for 10 min, the 
supernatant was collected and stored at -20°C until analysis. 
Preparation of the plasma sample
Plasma samples (50 μl) were transferred to centrifuge tubes. 
400 μl 6% perchloric acid in water and 400 μl methanol were 
added to the plasma. The mixture was mixed on a vortex for 2 
min, and then centrifuged at 8000× g for 15 min to precipitate 
protein. The supernatant was transferred to another tube, and 
the methanol was eliminated by evaporation at 40°C under a 
gentle stream of nitrogen. The residue I was extracted twice 
with 400 μl chloroform. The chloroform layer of the residue I 
was collected and evaporated to dryness at 40°C under a gentle 
stream of nitrogen. The residue II was dissolved in 200 μl of 
50% methanol solution and vortex-mixed for 2 min. The tubes 
were centrifuged at 18000× g for 10 min. The supernatants were 
transferred to vial inserts and 20 μl was injected into LC-MS/MS.
Calibration curve
The stock solution was diluted to give solutions of 0.01, 0.50, 
1.00, 2.51, 3.51 and 5.01 μg/ml; respectively. Each concentration 
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was injected in triplicate and the mean peak area was used for 
the calibration plot.
Precision
Dracorhodin (1) standard plasma solution (2.51 μg/ml) 
was sampled for LC-MS analysis. The work was repeated 
five times, and to calculate the accurate relative standard 
deviation (RSD %).
Repeatability
Five 2.51 μg/ml dracorhodin standard plasma solutions were 
sampled for LC-MS analysis, to explore the repeatability of the 
analysis method.
Stabilization
The FP plasma solution after oral administration was sampled 
for LC-MS analysis respectively after being prepared for 0, 4, 
8, 12, and 24 h to ensure stabilization of the solution. The 
concentration of dracorhodin was obtained by to the above-
mentioned chromatogram conditions.
Statistical analysis
All pharmacokinetic parameters were calculated using DAS 
software (Ver. 2.0, Mathematical Pharmacology Professional 
Committee of China). 
Results and discussion
Powder size distribution
The particle size distribution of the FP and SP can be seen in 
Fig. 1. The average particle size, D90 and D50 of the FP were 60.7 
μm, 164.5 μm and 28.9 μm, respectively. The average particle 
size, D90 and D50 of the SP were 30.1 μm, 32.2 μm and 5.2 μm, 
respectively.
Specific surface area and pore volume
The specific surface area (SSA) and pore volume of SP were 
significantly different (p < 0.05) compared with FP. The 
SP was found to have higher SSA and larger pore volume. 
Conversely, the FP had lower SSA and smaller pore volume 
(Table 1). Since higher SSA and pore volume may increase 
contact area with dissolution medium, they will have effect 
indirectly on drug dissolution from solid dosage forms (Riley 
et al., 2008).
Morphology analysis
The optical characteristics of Qili Powder are showen in Fig. 2. 
The eyepiece lens had a magnification of 20× and the objective 
lens was 40×. The magnification of polarizing microscope was 
800 times. In the FP, yellowish-brown long tubular secretory 
cell of Flos Carthami (a), ellipsoidal pollen grains of Flos Carthami 
(b), irregular sanguineous pieces around with bright yellow 
liquid of Sanguis draconis (c), irregular minute granules dark 
brownish-red lustrous and with dark black edges of cinnabar 
(d) were clearly observed. For SP (e), the cell walls were broken 
into pieces and optical microstructure characteristics of Sanguis 
draconis and cinnabar were disappeared.
Bulk density and the angle of repose
The bulk density (Ub) was the density including pores and 
interparticle voids. The Ub of the FP and SP were 0.3604 and 
Sample
Specific surface area 
(m2/g)
Pore volume 
(cm3/g)
FP 0.2998 ± 0.0051 0.000849 ± 0.000030
SP 2.0309 ± 0.0471* 0.007062 ± 0.000056*
Mean ± S.D., n = 3; *p < 0.05 compared to FP.
Table 1
Specific surface area and Pore volume of fine Qili powder (FP) 
and superfine Qili powder (SP).
Figure 1 – Particle size distribution of fine Qili powder (a) and 
superfine Qili powder (b).
Figure 2 – Optical microstructure of long tubular secretory cell 
of Flos Carthami in fine Qili powder (a), pollen grains of Flos 
Carthami in fine Qili powder (b), pieces of Sanguis draconis in 
fine Qili powder (c), granules of cinnabar in fine Qili powder 
(d), superfine Qili powder (e).
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0.3732 g/ml, respectively. The Ub varied significantly between 
the FP and SP (p < 0.05). This might be due to the fact that 
particle size decreases leading to bulk density increase. 
The angle of repose (T) could reflect the change in the 
fluidity of the powders (Ileleji et al., 2008). The T of FP and 
SP was 54.64° and 56.85°, respectively (Table 2). The results 
confirmed that superfine-treatment had a significant effect 
on T (p < 0.001). As T increased, the fluidity of powder bulk 
could diminish.
With the decreasing of particle size, the T of Qili Powder 
significantly increased (p < 0.001). This result is not in 
agreement with what the reports stated (Santomaso et al., 
2003; Zhao et al., 2009; 2010). The reason might be due to the 
fact that Sanguis draconis is the main component of Qili Powder, 
and is a cohesive medicinal material. Sanguis draconis in SP 
might have been exposed after superfine pulverization, which 
may be cause of the surface attachment of the SP was higher 
than that of FP, so the T of SP significantly increased and the 
fluidity diminished.
Moisture absorption
As shown in Figure 3, the powders with different particle 
size displayed a different curve of moisture absorption. 
The percentage of moisture absorption of FP and SP slowly 
increased before 36 h, and reached to balance after 36 h. It was 
interesting to note that both percentage of moisture absorption 
and balanced moisture content (BMC) decreased with the 
decrease of particle size and the increase of SSA. The reason 
might be related to the cohesive characteristic of Sanguis 
draconis, a main component in Qili Powder. Sanguis draconis 
of SP might have been exposed after superfine-treatment. A 
compact film had formed on the surface of SP after moisture 
absorption, which blocked up diffusion path of moisture that 
finally led to a decreased percentage of moisture absorption 
and BMC.
FTIR and XRD analysis
The FTIR spectra and XRD patterns of Qili Powder are shown 
in Figure 4. From Figure 4A we can see that no molecular 
structure change occurred between the SP and FP, because 
the characteristic peaks didn’t show any shifts. There were 
no differences between the characteristic diffraction peaks of 
FP and that of SP in Figure 4B, because the old characteristic 
peaks didn’t disappear and the new characteristic peaks 
didn’t appear. It meant that superfine pulverization didn’t 
change the molecular structure and crystal form of Qili 
Powder.
Content of dracorhodin 
The identification and quantification of the active ingredient 
are very important for quality control and efficacy of Qili 
Powder. The HPLC analysis showed that the dracorhodin 
(1) did not cause alterations in the chromatographic profile 
in relation to superfine pulverization (Fig. 5). The contents 
of dracorhodin in the FP and SP were 1.12 ± 0.02 mg/g and 
1.13 ± 0.01 mg/g, respectively. There was no significant 
difference in dracorhodin content between FP and SP. It 
means that superfine pulverizing didn’t influence the content 
of dracorhodin in Qili Powder. 
Sample Bulk density (g/ml) Angle of repose (°)
FP 0.3604 ± 0.0160 54.64 ± 0.60
SP 0.3732 ± 0.0133* 56.85 ± 0.36***
Mean ± S.D., n = 3; *p < 0.05 compared to FP; ***p < 0.001 compared to FP.
Table 2
Bulk density and angle of repose of fine Qili powder (FP) and 
superfine Qili powder (SP).
Figure 3 – Curve diagram of moisture absorption of fine Qili 
powder (FP) and superfine Qili powder (SP).
Figure 4 – FTIR spectra (A) and XRD patterns (B) of fine Qili 
powder (a) and superfine Qili powder (b).
Figure 5 – HPLC chromatogram of dracorhodin (1), fine Qili 
powder (FP) and superfine Qili powder (SP).
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Dissolution testing 
The percentage of dissolution of dracorhodin in the FP and SP 
was studied and the results are shown in Fig. 6. The results 
showed that lower percentage of dracorhodin dissolution in 
both FP and SP. This was due to the characteristic liposoluble 
nature of dracorhodin. However, it was clear that the percentage 
of dissolution of dracorhodin significantly increased with the 
decrease of particle size (p < 0.05). There was no difference in the 
content of dracorhodin between FP and SP therefore, the main 
factor affecting the dissolution of dracorhodin was proven to be 
the particle size and the SSA of Qili Powder.
Pharmacokinetics
The calibration plots were linear in the range of 0.01-5.01 μg/
ml. The mean of six different calibration plots yielded the 
equation Y = 34633X + 132710, R = 0.9909. The precision and 
repeatability of dracorhodin (1) standard plasma solution 
were 4.5 and 4.8%, respectively. These results showed that 
the precision and repeatability were favorable. The RSD of 
stabilization of FP plasma solutions after oral administration 
was 1.59%, which showed that the solution was stable in 24 h.
The mean plasma dracorhodin concentration–time curve 
after oral administration of the FP and SP was shown in 
Figure 7. All pharmacokinetic parameters were calculated 
Figure 6 – Curve diagram of dracorhodin dissolution (1) in fine 
Qili powder (FP) and superfine Qili powder (SP).
Figure 7 – Plasma dracorhodin (1) concentration-time curves 
after oral administration of fine Qili powder (FP) and superfine 
Qili powder (SP) (n = 6)
by DAS software. The major pharmacokinetic parameters 
were presented in Table 3. After superfine pulverization, the 
maximal plasma concentration (Cmax) of dracorhodin increased 
from 0.28 mg/ml to 3.06 mg/ml, while the peak time (Tmax) 
decreased from11.95 h to 2.10 h. This showed that the SP was 
absorbed faster than that of FP. The mean residence time (MRT) 
and the total body clearance rate (CLz/F) of dracorhodin of SP 
were 31.09 ± 6.14 h and 0.47 ± 0.14 l/h/kg, respectively, which 
was significantly different from FP (*p < 0.05, **p < 0.01). This 
indicated that the duration of drug effect has been prolonged 
after superfine pulverization. Therefore, the AUC(0-t) of 
dracorhodin in SP was 26.84 ± 7.77 mg/l*h, which was 3.75 times 
of the FP’s (**p < 0.01). This showed that the absorbption capacity 
of the medicine in rats was increased by superfine pulverization. 
The reason might be due to that the effective contact area 
of the medicine with the body fluid is increased when the 
medicine is pulverized to superfine powder. The results of the 
pharmacokinetics analysis showed that superfine powder has 
the advantage of faster absorption and higher bioavailability.
Paramaters FP SP
AUC(0-t)(mg/l*h) 7.15 ± 1.53 26.84 ± 7.77**
AUC(0-∞)(mg/l*h) 7.26 ± 1.51 27.42 ± 7.76**
MRT(0-t)(h) 22.25 ± 2.72 29.75 ± 5.67*
MRT(0-∞)(h) 23.37 ± 2.39 31.09 ± 6.14*
t1/2z(h) 10.69 ± 3.56 9.39 ± 4.36
CLz/F(l/h/kg) 1.75 ± 0.46 0.47 ± 0.14**
Cmax(mg/l) 0.28 ± 0.06 3.06 ± 1.50*
Tmax(h) 11.95 ± 11.31 2.10 ± 3.31*
F(%) 100 375.38
Mean ± S.D., n = 6; *p < 0.05 compared to FP; **p < 0.01 compared to FP.
Table 3
Pharmacokinetic Paramaters of dracorhodin (1) after oral 
administration of fine Qili powder (FP) and superfine Qili 
powder (SP)
Conclusions
SSA and the pore volume of Qili Powder after superfine 
pulverization increased. The fluidity of powders decreased 
with the decreasing of particle size. The percentage of moisture 
absorption and the balanced moisture content of SP decreased, 
which may result in a slow agglomeration of SP that finally leads 
to increased storage stability and prolonged period of guaranteed 
quality of Qili Powder. Compared with FP the superfine 
pulverization did not influence the content of dracorhodin 
nor the molecular structure and crystal form of Qili Powder, 
but significantly improved the percentage of dissolution and 
absorption of dracorhodin in rats. The superfine pulverization 
of Qili Powder showed some physicochemical and medicinal 
properties that might be of potential use in the drug industry. 
According to related works, the general view is that after 
superfine pulverization SSA of superfine powder increases, 
which results in easy moisture absorption. With the increase 
of water content, the stability of TCM preparation decreases, 
such as charging of chemical component, midewing and so 
on, and guaranteed quality period was shortened. However, 
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after superfine pulverization, the rate of moisture absorption 
and BMC of SP decreased. These results showed that maybe 
superfine pulverization could increase storage stability of Qili 
Powder and prolong guaranteed quality period of Qili Powder.
Our results suggested that fluidity was negatively related 
to the particle size of Qili Powder. The research group has 
studied Flos Carthami, Angelicae sinensis radix, Radix et rhizoma 
Notoginseng, Drynariae rhizoma, Radix et rhizoma Rhei, catechu, 
Sanguis draconis separately and got the same result. Bad fluidity 
was not conducive to subsequent processing of superfine 
powders, and may lead to a bigger load difference during the 
packing process of superfine powders.
To improve bioavailability of SP, the efficacy of superfine 
powders will be enhanced, which means that dosage can be 
reduced as well as the raw material, thus minimizing TCM 
materials, especially the tense situation of endangered TCM 
biological materials such as musk.
The Pharmacopoeia of the People’s Republic of China 
(2010 Edition) contains about 1036 kinds of TCM preparations. 
Among them, 742 kinds are used directly as a medicine in 
powder form after pulverization, which are about 72% of TCM 
preparations. It is clear now that a TCM powder is an important 
intermediate product or end product of TCM preparation. The 
physicochemical and medicinal properties of  a TCM powder 
is directly related to the particle size of powders. Thus, the 
physicochemical and medicinal properties of TCM preparations 
may improve by making TCM powders into superfine powders. 
Therefore, this study will not only helpful to the application 
of superfine pulverization in Qili Powder, but also provide a 
possible method to prepare other TCM powders.
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